Calidi Biotherapeutics Inc. reports a Return on Equity (ROE) of -385.57%.

What is CLDI's dividend yield?

Calidi Biotherapeutics Inc. offers a dividend yield of 0.00%.

What is CLDI's Quality Score?

Our AI rates CLDI's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CLDI?

Our AI Timing Score for CLDI is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CLDI belong to?

Calidi Biotherapeutics Inc. is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange

Calidi Biotherapeutics Inc. (CLDI) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2026-03-31)

CLDI AI Analysis Summary

Our AI summary for CLDI: Calidi Biotherapeutics Inc. (NYSE MKT), Healthcare >> Biotechnology sector. The stock currently trades at ROE of -385.57%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CLDI

Calidi Biotherapeutics Inc.

US:NYSE MKT STOCK Healthcare >> Biotechnology News 62

USD 1.76

-0.13 (-6.88%) Day Change

Watchlist Portfolio Compare Chart

0.43

D/E

-385.6%

ROE

-198.4%

ROA

0.00%

Div Yield

CALIDI BIOTHERAPEUTICS INC.
TYPE: STOCK
MARKET: NYSE MKT

Compare Watchlist Myport

USD 1.76 Price -0.13 (-6.88%) Day Change	NEWS SCORE: 62

CLDI, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	62
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	1.76
PBV / Sector	0.46 / 44,105.10 GREAT
Earning Per Share	-14.68

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.76 M GREAT
Average 1W Daily Value	0.38 M GREAT

Timing Factors

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 97.23
NPM Average (%) / Sector	-56,504.44 / -1,697.84
NPM Change Average (%) / Sector	N/A / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-198.39 / 185,260.64
ROA Average (%) / Sector	-370.00 / 36,684.64
ROA Change Average (%) / Sector	-21.11 / 422,221.42
ROE (%) / Sector	-385.57 / 243,761.81
ROE Average (%) / Sector	-390.68 / 48,758.38
ROE Change Average (%) / Sector	1.60 / 424,967.86
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 07:59:48
Symbol	CLDI
Name	CALIDI BIOTHERAPEUTICS INC.
Sector	Healthcare >> Biotechnology
Market	NYSE MKT
Listed Shares	1.21 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2.28 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 4475 Executive Drive, San Diego, CA, United States, 92121

Phone: 858 794 9600

Website: https://www.calidibio.com

Sector: Healthcare >> Biotechnology

Description: Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.